Literature DB >> 19370430

Impact of (18)F-FDG-PET/CT on staging and irradiation of patients with locally advanced rectal cancer.

Brigita Paskeviciute1, Tobias Bölling, Markus Brinkmann, Ganna Rudykina, Iris Ernst, Lars Stegger, Otmar Schober, Normann Willich, Matthias Weckesser, Stefan Könemann.   

Abstract

PURPOSE: To investigate the impact of fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) on planning of neoadjuvant radiotherapy for locally advanced rectal cancer (LARC) patients. PATIENTS AND METHODS: From January 2003 to December 2007, a total of 36 patients with LARC underwent a retroprospective PET/CT study for radiotherapy-planning purposes. Gross tumor volume (GTV), clinical target volume (CTV) and planning target volume (PTV) were defined in a retrospective analysis by a blinded reader. The hypothetical boost volume was defined primarily on CT alone, and afterwards on the fused PET/CT dataset. The CT- and PET/CT-based GTVs were quantitatively compared and percentage of overlap (OV%) was calculated and analyzed. The impact of PET/CT on radiation treatment planning and overall patient management was evaluated.
RESULTS: PET/CT-GTVs were smaller than CT-GTVs (p < 0.05). PET/CT imaging resulted in a change of overall management for three patients (8 %). In 16 of 35 patients (46 %), PET/CT resulted in a need for modification of the usual target volumes (CT-PTV) because of detection of a geographic miss.
CONCLUSION: FDG-PET/CT had significant impact on radiotherapy planning and overall treatment of patients with LARC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19370430     DOI: 10.1007/s00066-009-1962-3

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  43 in total

1.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

Authors:  E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

2.  Clinical implementation of intensity-modulated arc therapy (IMAT) for rectal cancer.

Authors:  Wim Duthoy; Werner De Gersem; Koen Vergote; Tom Boterberg; Cristina Derie; Peter Smeets; Carlos De Wagter; Wilfried De Neve
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-11-01       Impact factor: 7.038

3.  Impact of hybrid fluorodeoxyglucose positron-emission tomography/computed tomography on radiotherapy planning in esophageal and non-small-cell lung cancer.

Authors:  Vinai Gondi; Kristin Bradley; Minesh Mehta; Andy Howard; Deepak Khuntia; Mark Ritter; Wolfgang Tomé
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-01-01       Impact factor: 7.038

4.  Lateral lymph node metastasis is a major cause of locoregional recurrence in rectal cancer treated with preoperative chemoradiotherapy and curative resection.

Authors:  Tae Hyun Kim; Seung-Yong Jeong; Dong Hyun Choi; Dae Yong Kim; Kyung Hae Jung; Sung Ho Moon; Hee Jin Chang; Seok-Byung Lim; Hyo Seong Choi; Jae-Gahb Park
Journal:  Ann Surg Oncol       Date:  2007-12-05       Impact factor: 5.344

5.  Experimental evaluation of functional imaging for radiotherapy.

Authors:  Daniel Zips; Ala Yaromina; Christina Schütze; Katharina Wüllrich; Marie Krause; Mechthild Krause; Franziska Hessel; Wolfgang Eicheler; Annegret Dörfler; Kerstin Brüchner; Apostolos Menegakis; Xuanjing Zhou; Ralf Bergmann; Jörg van den Hoff; Bettina Beuthien-Baumann; Michael Baumann
Journal:  Strahlenther Onkol       Date:  2007-12       Impact factor: 3.621

6.  Adaptive RT in rectal cancer: superior to 3D-CRT? A simple question, a complex answer.

Authors:  Karin Haustermans; Sarah Roels; Jan Verstraete; Tom Depuydt; Pieter Slagmolen
Journal:  Strahlenther Onkol       Date:  2007-12       Impact factor: 3.621

7.  Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum.

Authors:  M H Whiteford; H M Whiteford; L F Yee; O A Ogunbiyi; F Dehdashti; B A Siegel; E H Birnbaum; J W Fleshman; I J Kodner; T E Read
Journal:  Dis Colon Rectum       Date:  2000-06       Impact factor: 4.585

Review 8.  Accurate staging, selective preoperative therapy and optimal surgery improves outcome in rectal cancer: a review of the recent evidence.

Authors:  I R Daniels; S E Fisher; R J Heald; B J Moran
Journal:  Colorectal Dis       Date:  2007-05       Impact factor: 3.788

9.  Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997.

Authors:  R J Heald; B J Moran; R D Ryall; R Sexton; J K MacFarlane
Journal:  Arch Surg       Date:  1998-08

10.  PET-CT fusion in radiation management of patients with anorectal tumors.

Authors:  Cynthia Anderson; Mary Koshy; Charles Staley; Natia Esiashvili; Sharam Ghavidel; Zach Fowler; Tim Fox; Fabio Esteves; Jerome Landry; Karen Godette
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-09-01       Impact factor: 7.038

View more
  6 in total

1.  Novel Carcinoembryonic-Antigen-(CEA)-Specific Pretargeting System to Assess Tumor Cell Viability after Irradiation of Colorectal Cancer Cells.

Authors:  Birgit Meller; Margarete Rave-Fränck; Christian Breunig; Markus Schirmer; Manfred Baehre; Roger Nadrowitz; Torsten Liersch; Johannes Meller
Journal:  Strahlenther Onkol       Date:  2011-01-24       Impact factor: 3.621

2.  Value of diffusion-weighted imaging in the detection of viable tumour after neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer: comparison with T2 weighted and PET/CT imaging.

Authors:  I Song; S H Kim; S J Lee; J Y Choi; M J Kim; H Rhim
Journal:  Br J Radiol       Date:  2011-02-22       Impact factor: 3.039

3.  Comparison of the micronucleus and chromosome aberration techniques for the documentation of cytogenetic damage in radiochemotherapy-treated patients with rectal cancer.

Authors:  Hendrik Andreas Wolff; Steffen Hennies; Markus Karl Alfred Herrmann; Margret Rave-Fränk; David Eickelmann; Patricia Virsik; Klaus Jung; Markus Schirmer; Michael Ghadimi; Clemens Friedrich Hess; Robert Michael Hermann; Hans Christiansen
Journal:  Strahlenther Onkol       Date:  2010-12-23       Impact factor: 3.621

Review 4.  The use of FDG-PET to target tumors by radiotherapy.

Authors:  Guido Lammering; Dirk De Ruysscher; Angela van Baardwijk; Brigitta G Baumert; Jacques Borger; Ludy Lutgens; Piet van den Ende; Michel Ollers; Philippe Lambin
Journal:  Strahlenther Onkol       Date:  2010-08-30       Impact factor: 3.621

5.  Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study.

Authors:  Dietmar Ofner; Alexander F Devries; Renate Schaberl-Moser; Richard Greil; Hans Rabl; Jörg Tschmelitsch; Matthias Zitt; Karin S Kapp; Gerd Fastner; Felix Keil; Wolfgang Eisterer; Robert Jäger; Felix Offner; Michael Gnant; Josef Thaler
Journal:  Strahlenther Onkol       Date:  2011-01-21       Impact factor: 3.621

Review 6.  Induction chemotherapy before chemoradiotherapy and surgery for locally advanced rectal cancer : is it time for a randomized phase III trial?

Authors:  Claus Rödel; Dirk Arnold; Heinz Becker; Rainer Fietkau; Michael Ghadimi; Ullrich Graeven; Clemens Hess; Ralf Hofheinz; Werner Hohenberger; Stefan Post; Rudolf Raab; Rolf Sauer; Frederick Wenz; Torsten Liersch
Journal:  Strahlenther Onkol       Date:  2010-11-30       Impact factor: 3.621

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.